A PHASE II RANDOMIZED STUDY OF PEMBROLIZUMAB IN PATIENTS WITH ADVANCED MALIGNANT PLEURAL MESOTHELIOMA

Registry ID

IND.227

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

CANADIAN CANCER TRIALS GROUP, CANCER RESEARCH INSTITUTE, QUEEN'S UNIVERSITY

Start date

2018-04-30

Last update

2016-05-20

Conditions

• PLEURAL MESOTHELIOMA

Related clinical trials

• A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER, GLOBAL STUDY OF VOLRUSTOMIG (MEDI5752) IN COMBINATION WITH CARBOPLATIN PLUS PEMETREXED VERSUS PLATINUM PLUS PEMETREXED OR NIVOLUMAB PLUS IPILIMUMAB IN PARTICIPANTS WITH UNRESECTABLE PLEURAL MESOTHELIOMA (EVOLVE-MESO)

View on source registry